A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 11, 2009, Pages 3389-3397

  Morena, Marion ^a   Dupuy, Anne Marie ^a,b   Jaussent, Isabelle ^b   Vernhet, Hélne ^a   Gahide, Gérald ^a   Klouche, Kada ^a   Bargnoux, Anne Sophie ^a   Delcourt, Cécile ^b   Canaud, Bernard ^a   Cristol, Jean Paul ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Chronic kidney disease; Coronary artery calcification; Osteoprotegerin

Indexed keywords

25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; CALCIUM PHOSPHATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY CALCIFICATION; DIAGNOSTIC VALUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CALCINOSIS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; KIDNEY DISEASE; MIDDLE AGED; PREDICTION AND FORECASTING; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCINOSIS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE;

EID: 73949116468     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp301     Document Type: Article

References (48)

1. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
2. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
3. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
4. Qunibi WY. Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16(Suppl 2): S95-S102
5. Russo D, Palmiero G, De Blasio AP, et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44: 1024-1030
6. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14(Suppl 4): S305-S309
7. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003
8. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-1057
9. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-1028
10. Browner WS, Lui LY and Cummings SR. Associations of serum os-teoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637
11. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180
12. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17: 262-270
13. Nitta K, Akiba T, Uchida K, et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886-1889
14. Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42: 303-309
15. Mazzaferro S, Pasquali M, Pugliese F, et al. Serum levels of calcification inhibition proteins and coronaryarterycalcium score: comparison between transplantation and dialysis. Am J Nephrol 2007; 27: 75-83
16. Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 2002; 14: 238-242
17. Badiou S, Dupuy AM, Descomps B, et al. Comparison between the enzymatic vitros assay for creatinine determination and three other methods adapted on the Olympus analyzer. J Clin Lab Anal 2003; 17: 235-240
18. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type-2 diabetic patients. Diabetes Care 2005; 28: 2176-2180
19. Mäimoun L, Couret I, Mariano-Goulart D, et al. Changes in osteopro-tegerin/RANKL system, bone mineral density and bone biochemical markers in patients with recent spinal cord injury. Calcif Tissue Int 2005; 76: 404-411
20. Levey AS, Coresh J, Greene T, et al. Using standardized serum creati-nine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254
21. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832
22. Raggi P, Bellasi A, Ferramosca E, et al. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007; 71: 802-807
23. Brindis RG, Douglas PS, Hendel RC, et al. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. J Am Coll Cardiol 2005; 46: 1587-1605
24. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007; 49: 378-402
25. Kramer H, Toto R, Peshock R, et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513
26. Tomiyama C, Higa A, Dalboni MA, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 2006; 21: 2464-2471
27. Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
28. Toussaint ND, Lau KK, Strauss BJ, et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 586-593
29. Parikh NI, Hwang SJ, Larson MG, et al. Indexes of kidney function and coronary artery and abdominal aortic calcium (from the Framingham Offspring Study). Am J Cardiol 2008; 102: 440-443
30. Ix JH, Katz R, Kestenbaum B, et al. Association of mild to moderate kidney dysfunction and coronary calcification. J Am Soc Nephrol 2008; 19: 579-585
31. Kronenberg F, Mundle M, Langle M, et al. Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am J Kidney Dis 2003; 41: 140-148
32. Sigrist M, Bungay P, Taal MW, et al. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006; 21: 707-714
33. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194
34. Anand DV, Lahiri A, Lim E, et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857
35. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-955
36. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
37. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007; 30: 2934-2939
38. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol 2006; 26: 2117-2124
39. Price PA, June HH, Buckley JR, et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616
40. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteoprote-gerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006; 169: 2236-2244
41. Xiang GD, Xu L, Zhao LS, et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006; 55: 2126-2131
42. Zauli G, Corallini F, Bossi F, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110: 536-543
43. Speer G, Fekete BC, Othmane TE, et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 3256-3262
44. Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008; 23: 3263-3271
45. Stompor T, Krzanowski M, Kusnierz-Cabala B, et al. Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis. Nephrol Dial Transplant 2006; 21: 3605-3606; author reply 3606
46. Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 2008; 13: 135-147
47. Kiechl S, Werner P, Knoflach M, et al. The osteoprote-gerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4: 801-811
48. Matias PJ, Ferreira C, Jorge C, et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 611-618